OR WAIT null SECS
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
Validating computerized systems is required to demonstrate adherence to data integrity, says Susan J. Schniepp, distinguished fellow at Nelson Laboratories, LLC.
Quality-by-design risk assessment workflows can be laborious and have limited capacity to connect with vast volumes of prior knowledge generated by organizations. ecosystem.
June 26, 2023
FDA’s new draft guidance outlines key considerations for psychedelic drug development programs.
June 21, 2023
The new guidelines contain formulation recommendations for vaccines launching in autumn 2023.
FDA’s new voluntary pilot program is designed to help clinicians select appropriate cancer treatments for patients.
June 16, 2023
There is concern that debates will delay the five-year reauthorization of PEPFAR under review by Congress.
June 08, 2023
The complaint alleges that Medicaid price controls implemented in the Inflation Reduction Act will negatively impact biopharmaceutical innovation.
June 07, 2023
Under the €35 million (US$37 million) investment, MilliporeSigma will expand its sites in Glasgow and Stirling, Scotland, to increase biosafety testing for drug development and commercialization.
June 05, 2023
Reimbursement for Alzheimer's medicines still will occur only with the completion of studies to support full FDA approval.
FDA has published a new system for providing basic and essential information on patient use of drugs and certain biologic products.
June 02, 2023
Manufacturers must figure out how flexible they need to be to meet the numerous new requirements of the changing therapeutic and regulatory landscapes.
What implications will EMA’s recent regulatory reform have on pharma?